Seeing Is Believing
Currently out of the existing stock ratings of Mara Goldstein, 130 are a BUY (75.58%), 40 are a HOLD (23.26%), 2 are a SELL (1.16%).
Analyst Mara Goldstein, currently employed at MIZUHO, carries an average stock price target met ratio of 43.43% that have a potential upside of 37.13% achieved within 236 days.
Mara Goldstein’s has documented 320 price targets and ratings displayed on 33 stocks. The coverage is on Healthcare, Communication Services sectors.
Most recent stock forecast was given on RCUS, Arcus Biosciences at 30-Jan-2024.
Analyst best performing recommendations are on FTSV (FORTY SEVEN).
The best stock recommendation documented was for CRVS (CORVUS PHARMACEUTICALS) at 3/30/2023. The price target of $3.5 was fulfilled within 69 days with a profit of $2.71 (343.04%) receiving and performance score of 49.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$101
$-7.24 (-6.69%)
$101
4 years 11 months 11 days ago
2/8 (25%)
$-7.53 (-6.94%)
171
Hold
$115
$6.76 (6.25%)
$102
4 years 11 months 11 days ago
3/12 (25%)
$6.47 (5.96%)
382
Hold
$100
$-8.24 (-7.61%)
$128
5 years 1 months 23 days ago
3/6 (50%)
$4.78 (5.02%)
159
Buy
$102
$-6.24 (-5.76%)
$105
5 years 5 months 9 days ago
3/3 (100%)
$5.12 (5.28%)
270
Hold
$100
$-8.24 (-7.61%)
$100
5 years 6 months 7 days ago
2/7 (28.57%)
$5.2 (5.49%)
282
What Year was the first public recommendation made by Mara Goldstein?